Celgene (now Bristol Myers Squibb)

Celgene was a major biopharmaceutical company with active corporate venture investments. Acquired by Bristol Myers Squibb in 2019 for $74B. Historical investments in genomics, cell therapy, and oncology continue under BMS umbrella.